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Abstract
Introduction: Human 17beta-hydroxysteroid dehydrogenase type 1 (17b-HSD1) is a steroid-converting enzyme
that has long been known to play critical roles in estradiol synthesis and more recently in dihydrotestosterone
(DHT) inactivation, showing a dual function that promotes breast cancer cell proliferation. Previously, we reported
the first observation of the influence of the enzyme on endogenous estrogen-responsive gene expression. Here,
we demonstrate the impact of 17b-HSD1 expression on the breast cancer cell proteome and investigate its role in
cell migration.
Methods: 17b-HSD1 was stably transfected in MCF7 cells and the proteome of the generated cells overexpressing
17b-HSD1 (MCF7-17bHSD1 cells) was compared to that of the wild type MCF7 cells. Proteomics study was
performed using two-dimensional gel electrophoresis followed by mass spectrometry analysis of differentially
expressed protein spots. Reverse transcription quantitative real-time PCR (RT-qPCR) was used to investigate the
transcription of individual gene. The effect of 17b-HSD1 on MCF7 cell migration was verified by a wound-healing
assay.
Results: Proteomic data demonstrate that the expression of more than 59 proteins is modulated following 17b-
HSD1 overexpression. 17b-HSD1 regulates the expression of important genes and proteins that are relevant to cell
growth control, such as BRCA2 and CDKN1A interacting protein (BCCIP) and proliferating cell nuclear antigen
(PCNA) which are down- and upregulated in MCF7-17bHSD1 cells, respectively. RT-qPCR data reveal that 17b-HSD1
increases the mRNA levels of estrogen receptors (ER) alpha and beta by 171 and 120%, respectively, while
decreasing that of the androgen receptor by 64%. Interestingly, 17b-HSD1 increases the mRNA transcript (by 3.6
times) and the protein expression of the metastasis suppressor gene nm23-H1 and the expression of the two
enzymes are closely correlated. We have further shown that 17b-HSD1 expression is associated with an increase of
MCF7 cell migration.
Conclusions: In addition to the regulation of important genes, we have demonstrated for the first time that 17b-
HSD1 increases breast cancer cell migration, in spite of its positive regulation of the antimetastatic gene NM23. This
is also correlated to its stimulation of breast cancer cell growth, further confirming its targeting in ER positive
breast cancer. The novel findings in this study suggest several directions for future research on the contribution of
17b-HSD1 to breast cancer progression and related treatment.
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Introduction
Breast cancer is the most frequent cancer affecting
women. The malignancy accounts for about one in ten
cancers in the world and is diagnosed in one million
women each year [1,2]. In North America, breast cancer
is the second most important cause of death from can-
cer in women, after lung cancer, and the leading cause
of cancer death among those between 20 and 59 years
of age [3,4]. After increasing through the 80s and 90s,
breast cancer incidence rates showed a welcome
decrease of 3.5% per year from 2001 to 2004 and the
mortality rate decreased by 1.9% per year in the United
States between 1998 and 2006 [3,5]. This reflects an
improvement in the diagnosis and treatment of the dis-
ease, yet it remains of prime importance.
Epidemiological evidence indicates that most breast
cancer risk factors are associated with prolonged expo-
sure of the mammary gland to high levels of estradiol
(E2). This potent estrogen plays a crucial role in the
development and evolution of hormone-dependent
breast cancer [6]. About 60% of premenopausal and 75%
of postmenopausal breast cancer patients show a hor-
mone dependency [7]. The final steps of E2 biosynthesis
implicate two principal pathways in breast cancer tissue:
the aromatase pathway transforms androgens into estro-
gens, and the sulfatase pathway converts the inactive
hormones estrone sulfate (E1S) and dehydroepiandros-
terone sulfate (DHEA-S) into estrone (E1) and dehy-
droepiandrosterone (DHEA), respectively, via the action
of steroid sulfatase (STS). Different enzymes further
convert DHEA to 5a-androstene-3b,17b-diol (A-diol)
and the latter to testosterone which can in turn be con-
verted to E2 by aromatase. The inactive E1, synthesized
by both STS and aromatase, is converted to the potent
E2 by the action of reductive 17beta-hydroxysteroid
dehydrogenases (17b-HSDs) [8-10]. In breast cancer
cells, E2 is principally synthesized by 17b-HSD type 1
(17b-HSD1), with the reduced form of nicotinamide
adenine dinucleotide phosphate (NADPH) as a cofactor.
Previously, we reported the dual function of 17b-HSD1
in estradiol synthesis and dihydrotestosterone (DHT)
inactivation stimulating cell proliferation [11]. Analyses
of 17b-HSD1 mRNA expression in breast carcinoma
specimens from patients revealed that high expression
of the enzyme correlates with a weak prognosis for
breast cancer [12-14]. Despite these observations, the
relationship between 17b-HSD1 expression and that of
genes and proteins involved in breast cancer cell growth
has not been established. The aim of the present study
was to investigate the impact of 17b-HSD1 overexpres-
sion on the protein profile of breast cancer cells. The
MCF7 cell line is a human hormone-dependent breast
cancer cell line widely used for breast cancer studies
that expresses both estrogen and androgen receptors.
Since the cell line barely expresses endogenous 17b-
HSD1 [11,15], we used it as cell model for the increase
of 17b-HSD1 expression. The proteomic approach using
two-dimensional gel electrophoresis is the most popular
tool to study global changes in protein profile following
biological or chemical treatments. We thus used this
technique to analyse the proteomic modification of
MCF7 cells in response to 17b-HSD1 overexpression.
Following the proteomics analysis, reverse transcription
quantitative real-time PCR (RT-qPCR) was used to
investigate the gene transcription of a number of differ-
entially expressed proteins, such as proliferating cell
nuclear antigen (PCNA) and the metastasis suppressor
gene nm23-H1. The overexpression experiments, com-
bined with further siRNA knockdown analysis, demon-
strated a strong positive correlation between nm23-H1
regulation and 17b-HSD1 expression. We thus hypothe-
sized that 17b-HSD1 could be implicated in breast can-
cer cell metastasis and evaluated its effect on MCF7 cell
migration.
Materials and methods
Cell culture and generation of stably-transfected MCF7-
17bHSD1 cells
Wild type (WT) MCF7 and T47D cells were cultured as
previously described, with MCF7 cell culture medium
containing 1 nM b-E2 [11]. Recombinant plasmid con-
taining 17b-HSD1 cDNA and the 17b-HSD1 stably
transfected-MCF7 cells (MCF7-17bHSD1 cells) were
generated as previously described [11].
Generation of protein extracts for proteomics analysis
WT MCF7 and MCF7-17bHSD1 cells were defrosted at
the same time and cultured in flasks (75 cm2 growth
area) in complete medium containing b-E2. After three
passages, cells were seeded into 10 cm diameter dishes
and cultured until reaching the desired confluence. For
protein sample preparation, cells having reached 80 to
90% confluence were washed twice with cold phosphate-
buffered saline (PBS) and scraped with a rubber police-
man in 1.2 mL PBS. Cells were collected in eppendorf
tubes (Eppendorf, Mississauga, Ontario, Canada) and
centrifuged at 3000 rpm for 5 minutes. The cell pellets
were re-suspended in 500 μL lysis buffer T8 (7 M urea,
2 M thiourea, 3% CHAPS, 20 mM DTT, 5 mM TCEP,
0.5% IPG buffer pH 4-7, 0.25% IPG buffer pH 3-10) con-
taining 50 mM tris-HCl pH 8.8, 1 mM phenylmethylsul-
fonyl fluoride (PMSF) and 1% protease inhibitors cocktail
(EMD Chemicals, Gibbs-town, NJ, USA). Protein samples
were precipitated using the two-dimensional Clean-Up
Kit (GE Healthcare, Piscataway, NJ, USA) and resolubi-
lized in T8 buffer. The protein samples included three
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independent biological replicates (coming from three
independent cell culture experiments), representing total
proteins from each cell line (MCF7 and MCF7-
17bHSD1) for a total of six samples. The protein concen-
trations were determined using the two-dimensional
Quant Kit (GE Healthcare, Piscataway, NJ, USA).
Two-dimensional gel electrophoresis
For the first dimension, 200 µg total protein samples
from MCF7 and MCF7-17bHSD1 cells were loaded onto
24-cm pH 4-7 immobilized pH gradient (IPG) strips
(Immobiline DryStrips; GE Healthcare). Strips were rehy-
drated for 10 hours at 30 volts and isoelectric focusing
was performed on an IPGphorII IEF system (GE Health-
care). For the second-dimension sodium dodecyl sul-
phate-polyacrylamide gel electrophoresis (SDS-PAGE),
focused Immobiline DryStrips were equilibrated twice for
15 minutes in an equilibration buffer (50 mM tris-HCl
pH 8.8, 6 M urea, 30% glycerol, 2% SDS, trace of bromo-
phenol blue) containing 10 mg/mL DTT for the first
equilibration and 25 mg/mL iodoacetamide for the sec-
ond one. Immobiline DryStrips were then transferred
onto the surface of a 12% acrylamide gel (20 × 25 ×
0.1 cm) and sealed using 0.5% agarose. Gels were run in
an Ettan DALTtwelse system (GE Healthcare) in a stan-
dard tris-glycine SDS-PAGE buffer at 40 mA/gel and
15oC until the tracking dye reached the end of the gel.
Three independent protein samples coming from three
independent cell culture experiments were run for each
cell line. Gels were fixed overnight in 40% methanol, 7%
acetic acid, stained with Sypro Ruby (Invitrogen, Burling-
ton, Ontario, Canada) and scanned with the ProXpress
CCD scanner (PerkinElmer, Waltham, MA, USA). The
two-dimensional gel electrophoresis was performed on
the Proteomic Platform of the Infectious Disease
Research Center (Québec, Canada).
Two-dimensional gel image analysis
Protein spot detection, spot matching and semiquantita-
tive statistical analysis were performed using the Progen-
esis software version PG240 (Nonlinear Dynamics,
Durham, NC, USA). For each cell line, three different gel
images were analyzed and a corresponding synthetic
image reference was obtained. After computer matching,
detected spots and spot matches were manually edited
for better accuracy. A spot had to be present in at least
two of the three replicate gels to be considered in the
analysis. The detection of protein spots differentially
expressed was performed using the t-test (P < 0.05) and
the Intelligent Noise Correction Algorithm (INCA)
volume and proteins that were differentially expressed
two-fold or higher were considered significant. Eighteen
protein spots were selected among the differentially
expressed spots and were excised from Sypro Ruby-
stained two-dimensional gels using a ProXcision robot
(PerkinElmer, Waltham, MA, USA) and sent for mass
spectrometry (MS) analysis.
Mass spectrometry and protein identification
MS experiments were performed by the Proteomics
Platform of the Eastern Quebec Genomics Center (Qué-
bec, Canada). Protein spots were washed with water and
tryptic digestion was performed on a MassPrep liquid-
handling robot (Waters, Milford, MA, USA) according
to the manufacturer’s specifications and the protocol of
Shevchenko et al. [16], with the modifications suggested
by Havlis et al. [17]. Peptide samples (aliquots of the
digested protein samples) were separated by online
reversed-phase (RP) nanoscale capillary liquid chromato-
graphy (nano LC) and analyzed by electrospray tandem
mass spectrometry (ES-MS/MS). The experiments were
performed with a Thermo Surveyor MS pump con-
nected to an LTQ linear ion trap mass spectrometer
(Thermo Fisher Scientific, San Jose, CA, USA) equipped
with a nanoelectrospray ion source (Thermo Fisher
Scientific). Peptide separation took place on a PicoFrit
column BioBasic C18, 10 cm × 0.075 mm internal dia-
meter (New Objective, Woburn, MA, USA) with a linear
gradient from 2 to 50% solvent B (acetonitrile, 0.1% for-
mic acid) in 30 minutes, at 200 nL/min (obtained by
flow-splitting). Mass spectra were acquired using a data
dependent acquisition mode using Xcalibur software
version 2.0 (Thermo Fisher Scientific). Each full scan
mass spectrum (400 to 2000 m/z) was followed by colli-
sion-induced dissociation of the seven most intense
ions. The dynamic exclusion (30 seconds exclusion
duration) function was enabled, and the relative colli-
sional fragmentation energy was set to 35%.
All MS/MS samples were analyzed using the Mascot
algorithm (Matrix Science, London, UK; version Mascot)
and the Uniref100_14_0_Homo_sapiens_9606 database
(version with 89892 entries). Mascot was searched with
a fragment ion mass tolerance of 0.50 Da and a parent
ion tolerance of 2.0 Da. Iodoacetamide derivative of
cysteine was specified as a fixed modification and oxida-
tion of methionine was specified as a variable modifica-
tion. Two missed cleavages were allowed.
Scaffold (version Scaffold_2_01_02, Proteome Software
Inc., Portland, OR, USA) was used to validate MS/MS-
based peptide and protein identifications. The protein
identification cut off was set at a confidence level of
95% (Mascot score > 33) with at least two peptides
matching to a protein. Proteins that contained similar
peptides and could not be differentiated based on MS/
MS analysis alone were grouped to satisfy the principles
of parsimony.
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Reverse transcription quantitative real-time PCR and
semiquantitative RT-PCR
Total RNA was isolated from cells using Trizol Reagent
(Invitrogen, Burlington, Ontario, Canada) in 6-well plates
and treated with DNase 1. Analysis of the RNA integrities
using the Bioanalyzer 2100 (Agilent Technologies, Missis-
sauga, Ontario, Canada) and the RNA 6000 Nano Chips
(Agilent Technologies, Mississauga, Ontario, Canada)
showed good qualities for all the RNA samples with RNA
integrity numbers (RIN) higher than 8/10. RNA samples
for RT-qPCR analyses comprised two biological repeti-
tions for each condition and cell line. For each sample,
mRNA quantifications were performed twice as previously
described [11,18] with Atp5o, Hprt1 and G6PD genes used
as internal controls. The procedures were performed at
the Q_RTPCR Platform service at CHUQ-CHUL Research
Center (Quebec, Canada). The primers used for the ampli-
fication and the corresponding cDNA fragments of each
mRNA are shown in Additional file 1. The mRNA levels
were expressed as mRNA copies/µg total RNA.
Semiquantitative RT-PCR was carried out and ana-
lyzed as previously described [11] except for the number
of cycles, which was 30.
siRNA synthesis and transfection
The sense and antisense sequences of three 17b-HSD1
siRNAs were selected and synthesized as previously
described [11]. Transfection of T47D cells with siRNA
was carried out in 6-well plates using Lipofectamine siR-
NAMax (Invitrogen), 3x105 cells/well and 200 nM mixed
17b-HSD1-specific siRNAs.
For cell migration assays, MCF7-17bHSD1 cells were
transfected with 100 nM mixed 17b-HSD1-specific siR-
NAs in 3.5 cm diameter dishes. Control cells were trans-
fected with scramble (control) siRNA [11].
Cell migration assay
Cell migration was evaluated by using a wound-healing
assay. First, MCF7 and MCF7-17bHSD1 cells were culti-
vated in 75 cm2 culture flasks in complete growth med-
ium. Cells, at low passage number, were seeded at high
density into 3.5 cm diameter dishes in E2-free medium
containing 5% fetal bovine serum (FBS). Two days later,
straight scratches were made in triplicate across confluent
monolayer cultures using a p200 micropipette tip. There-
after, cells were washed five times with fresh E2-free med-
ium and were incubated in the same medium. Second,
MCF7-17bHSD1 cells were transfected with 17b-HSD1-
specific siRNAs or scramble siRNA (control siRNA) in
3.5 cm diameter dishes in complete growth medium, and
were incubated. Forty-eight hours after transfection, a
wound was created by manually scraping the cell mono-
layer as described above. Cells were then washed five
times and incubated in E2-free medium containing 5%
FBS. All experiments were done in quadruplicate. The
movements of cells in the scratched area were monitored
by capturing images every 15 minutes for a total duration
of 48 hours using the ×10 objective lens of a phase-con-
trast microscope. The scratch widths were measured at
specific time points using the NIH ImageJ software.
Western blot
WT MCF7 and MCF7-17bHSD1 cells were cultured in
complete medium containing b-E2 and total proteins were
extracted from cells with complete T8 lysis buffer. Equal
volumes of proteins were separated by 12% SDS-PAGE
and then electro-blotted onto nitrocellulose membranes.
The membranes were blocked with 5% non-fat milk in
PBS-tween 20 (PBS-T) for one hour at room temperature.
After blocking, the membranes were incubated for two
hours at room temperature in 5% non-fat milk in PBS-T
containing the following primary antibodies against the
indicated proteins: 17b-HSD1 (1:100,000 dilution of
ab51045) from Abcam (Cambridge, MA, USA), PCNA
(1:500 dilution of sc-7907), nm23-H1 (1:500 dilution of sc-
343), BCCIP (1:300 dilution of SC-130898) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), and b-actin
as the internal control (1:7,500 dilution of a monoclonal
antibody, from Sigma). Next, membranes were incubated
for one hour at room temperature with a horseradish per-
oxidase-conjugated secondary antibody (Santa Cruz Bio-
technology) diluted 10,000 times. Protein signals were
visualized with Chemiluminescence Reagent (PerkinElmer)
and bands were quantified using the NIH ImageJ software.
The ratios between the signals of the protein of interest
and b-actin were calculated to determine the relative pro-
tein expression values.
Results
Overexpression of 17b-HSD1 modulates the protein
profile of MCF7 cells
To investigate the proteomic modifications of MCF7 cells
in response to 17b-HSD1 overexpression, we performed
two-dimensional gel analysis using total protein lysates of
the WT breast cancer cell line MCF7 and MCF7 cells
overexpressing 17b-HSD1 cultured in medium containing
E2. We then compared the proteomic profile of the two
cell lines. To do so, we first stably transfected WT MCF7
cells with a 17b-HSD1 plasmid to generate the 17b-HSD1
stably transfected cells (MCF7-17bHSD1 cells). Western
blot showed an increase in 17b-HSD1 expression in the
MCF7-17bHSD1 cells (Figure 1A). Proteomic analyses
were carried out on six two-dimensional electrophoresis
gels made from three independent biological repetitions of
protein samples from MCF7-17bHSD1 cells and the par-
ent cells. The two cell lines displayed similar spot patterns
(Figure 1B) which allowed a good spot alignment for the
proteome comparison. MCF7-17bHSD1 protein samples
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Figure 1 Proteomic analysis of wild type (WT) MCF7 cells and MCF7 cells stably transfected with 17b-HSD1 (MCF7-17bHSD1). (A)
17beta-hydroxysteroid dehydrogenase type 1 (17b-HSD1) and b-actin expression between WT MCF7 and MCF7-17bHSD1 revealed by western
blots. (B) Representative two-dimensional gel images for WT MCF7 and MCF7-17bHSD1 cells. Whole cell lysates (200 µg) from each cell were
separated by two-dimensional electrophoresis and visualized by Sypro Ruby staining. The two-dimensional gels were scanned and the
differentially expressed (2-fold or higher, P < 0.05) proteins were detected using Progenesis software. The 18 differentially expressed protein
spots that were selected for mass spectrometry (MS) analysis are marked with circles. Protein spots upregulated in MCF7-17bHSD1 are depicted
in the MCF7-17bHSD1 proteome image; protein spots downregulated in MCF7-17bHSD1 are depicted in the MCF7 proteome image. The
numbers refer to the spot number listed in Table 1 and Additional file 2. The squares represent the indicated area shown in more detail in (D).
(C) Summary of the numbers of spots and proteins obtained from the proteomics data. *Upregulated (up) and downregulated (down) proteins
in MCF7-17bHSD1 as compared to WT MCF7 cells. (D) Zoom showing some differentially expressed protein spots from WT MCF7 and MCF7-
17bHSD1 comparison. Arrows indicate 17b-HSD1 protein which was revealed by MS analysis to be present in the spot numbers 2,305 (unique to
MCF7-17bHSD1) and 2,300 (upregulated in MCF7-17bHSD1 as compared to WT MCF7 cells).
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exhibited a lower number of protein spots (3,024) than
MCF7 (3,132 spots). The proteomic analyses using the
Progenesis software and a t-test (with a P-value < 0.05)
identified 30 significant differential protein spots between
MCF7 and MCF7-17bHSD1 as follows: 5 spots downregu-
lated and 13 spots upregulated in MCF7-17bHSD1 as
compared to MCF7, for a total of 18 spots that varied 2-
fold or more, while 7 and 5 spots were unique to MCF7
and MCF7-17bHSD1 samples, respectively (Figure 1C).
The analyses by MS of 18 protein spots (Figure 1B),
selected among the differentially expressed spots,
allowed the identification of proteins with a known Uni-
Prot accession number among all the spots for a total of
73 proteins. The numbers of proteins found in each cell
line are listed in Figure 1C. Some spots contained more
than one protein and some proteins were present in
more than one spot. For example, 17b-HSD1 was identi-
fied in the spot numbers 2,300 and 2,305 (Figure 1B and
1D). This resulted in the identification of 59 distinct
proteins distributed as follows: 15 and 9 proteins from
spots unique to MCF7 and MCF7-17bHSD1 respec-
tively, and 35 proteins from spots upregulated in either
cell line. These results showed that 17b-HSD1 modu-
lates protein profile in MCF7 cells.
Using the UniProt database [19], we determined the
subcellular locations and functions (or biological pro-
cesses) of each of the 59 proteins identified by MS analysis.
The original spot for each protein, the spot fold-increase
or fold-decrease in one cell line versus another cell line,
the protein name, the molecular mass, the isoelectric
point, the number of unique peptides allowing the protein
identification in the MS analysis, and the UniProt acces-
sion number of the protein are listed (Table 1; see Addi-
tional file 2 for additional data). The information about
the molecular function and/or biological process was
found for most proteins. Important proteins involved in
cell proliferation were differentially expressed following
17b-HSD1 overexpression. These proteins include PCNA,
peroxiredoxin 2, BRCA2 and CDKN1A interacting protein
(BCCIP) and ribonuclease/angiogenin inhibitor 1 (RNH1).
Intriguingly, the metastasis inhibition factor nm23 (nm23-
H1), an enzyme known to act as a downregulator of breast
cancer metastasis, was upregulated by 17b-HSD1 and
found in a spot unique to MCF7-17bHSD1 as compared
to MCF7. The repartitions of the functions and subcellular
locations of the 59 differentially expressed proteins are
illustrated and the percentages of proteins involved in
each molecular function and found in each cellular loca-
tion are indicated (Figure 2). Overexpression of 17b-HSD1
in MCF7 cells causes a differential expression of proteins
that act mainly in metabolism (5.5% upregulated protein
and 5.5% repressed), mRNA processing (3.1% induced and
7.9% repressed), protein biosynthesis (9%) and transport
(8%). Differentially expressed proteins are mainly located
in the cytoplasm and nucleus.
In order to verify the differential expression of individual
proteins in MCF7 and MCF7-17bHSD1, we performed
western blot analysis on total protein extracts for three of
the identified proteins, PCNA, nm23-H1 and BCCIP.
The differential expression of PCNA and nm23-H1 in
MCF7 and MCF7-17bHSD1 was confirmed. However,
BCCIP barely exhibited a protein band and thus, the
observed relative protein expression values in the two
cell lines should be considered with caution (Figure 3A
and 3B).
The mRNA levels of enzymes involved in cell proliferation
are regulated by 17b-HSD1
Next, we investigated if 17b-HSD1 influences the tran-
scription of genes involved in cell proliferation. To do this,
six proteins involved in cell proliferation, cancerogenesis
or metastasis regulation were selected: PCNA, peroxire-
doxin 2, nm23-H1, S-phase kinase-associated protein 1
(SKP1), BCCIP and RNH1. Their mRNA levels were mea-
sured by RT-qPCR analysis of total RNA extracts from
MCF7 and MCF7-17bHSD1 cell lines (Table 2). The
increases in mRNA levels of PCNA, peroxiredoxin 2,
nm23-H1 and BCCIP following 17b-HSD1 overexpression
were significant (more than 2-fold). The most regulated
mRNA is that of nm23-H1 which was 3.6-fold higher in
MCF7-17bHSD1 cells than in MCF7 cells (Table 2).
We further evaluated the correlation between mRNA
and protein levels by comparing data from the RT-qPCR
and the proteomic analyses. Proteomics and RT-qPCR data
were considered to correlate if the mRNA level and protein
spots were regulated in the same direction. It must be
noted that the observed correlations are semiquantitative,
since two-dimensional gel data are considered semiquanti-
tative, and some spots contained more than one protein. In
addition, some proteins were found in several spots, which
can be the effect of post-translational modifications [20].
When comparing MCF7-17bHSD1 to MCF7, we found
that RNH1, a regulator of angiogenesis, was downregulated
at both protein and transcript levels, whereas PCNA, SKP1
and nm23-H1 were upregulated at both protein and tran-
script levels. With the exception of peroxiredoxin-2 (which
is an anti-apoptosis protein) and BCCIP (a promoter of cell
cycle arrest), all the other four proteins for which the
mRNA expression was evaluated exhibited regulation in
the same direction for protein and mRNA in MCF7-
17bHSD1 as compared to MCF7 (Table 2). These data can
indicate the existence of a semiquantitative correlation
between protein and mRNA expression. Thus, it may be
possible to predict the presence of a protein based on its
gene expression or inversely. However, as suggested in a
previous study [21], the correlation between mRNA and
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protein levels may not be sufficient to predict protein
expression levels from quantitative mRNA data.
Transcription of various genes involved in E2 production
Because 17b-HSD1 is a pivotal enzyme in the synthesis
of E2, a hormonal steroid playing a major role in breast
cancer induction and progression, we were interested to
know if its overexpression in MCF7 cells would influ-
ence the expression of other genes involved in the hor-
mone synthesis, inactivation and action. The mRNA
levels of these proteins, which include 17b-HSDs type 2
(17b-HSD2), type 5 (17b-HSD5), type 7 (17b-HSD7),
type 12 (17b-HSD12), aromatase (or P450arom), estro-
gen sulfotransferase (EST), STS, androgen receptor
Table 1 Mass spectrometry identification of proteins differentially expressed between wild type MCF7 cells and MCF7
cells stably transfected with 17b-HSD1 (MCF7-17bHSD1).







Pep Function and/or biological process
Spot downregulated in MCF7-17bHSD1 as compared to WT MCF7




O14745 58/39 5.3 17 Wnt signaling pathway
3252 2.3 Neudesin Q9UMX5 19/19 4.7 2 Neuronal differentiation and proliferation
1703 2.2 Ribonuclease/angiogenin inhibitor 1 (RNH1)
(3177)
a
P13489 58/50 4.6 24 Regulation of angiogenesis, mRNA catabolism
BRCA2 and CDKN1A interacting protein
(BCCIP)a
Q9P287 58/36 4.6 4 Promote cell cycle arrest
Cell division cycle protein 123 homolog O75794 58/39 4.6 2 Required for S phase entry of the cell cycle
Spot unique to WT MCF7
2617 U Poly(rC)-binding protein 2 Q15366 32/39 6.4 11 RNA binding
Purine nucleoside phosphorylase P00491 32/32 6.4 6 DNA modification
BTB/POZ domain-containing protein KCTD15 Q96SI1 32/32 6.4 4 Potassium ion transport
RING finger protein 114 Q9Y508 32/26 6.4 2 Cell differentiation
4335 U Peptidyl-prolyl cis-trans isomerase E Q9UNP9 35/33 5.4 10 Protein folding, mRNA splicing
Transgelin-2 P37802 20/22 5.6 8 Muscle development
Splicing factor, arginine/serine-rich 2 Q01130 35/25 5.4 2 mRNA processing
3039 U RAB11B protein A5YM50 24/25 5.7 11 Protein transport, signal transduction
Peroxiredoxin-2a P32119 24/22 5.7 6 Cell redox regulation, anti-
apoptosis
Splicing factor, arginine/serine-rich 3 P84103 24/19 5.7 2 RNA processing in relation with cell proliferation
Spot upregulated in MCF7-17ΒHSD1 as compared to WT MCF7
2714 2.5 Exosome complex exonuclease RRP41 Q9NPD3 29/26 6.2 3 rRNA processing
Enoyl-CoA hydratase, mitochondrial P30084 29/31 6.2 6 Fatty acid and lipid metabolism
Heat shock 70 kDa protein 1 P08107 29/70 6.2 5 Stress response
Eukaryotic translation initiation factor 4H Q15056 29/27 6.2 4 Host-virus interaction, protein biosynthesis
2496 4.9 Proliferating cell nuclear antigen (PCNA)a P12004 32/29 4.6 16 DNA replication
5474 4.0 Myosin regulatory light chain 2,
nonsarcomeric
P19105 20/20 4.7 5 Cytokinesis, receptor capping, cell locomotion
2300 3.3 60S acidic ribosomal protein P0(2305) A8K4Z4 40/34 5.6 6 Ribosome biogenesis, translation elongation
Spot unique to MCF7-17ΒHSD1
2305 U 17b-hydroxysteroid dehydrogenase type 1
(2300)
P14061 41/35 5.4 22 Steroid biosynthesis
3177 U Metastasis inhibition factor nm23 (nm23-H1)a P15531 21/17 5.9 6 Cell cycle and proliferation,
nucleotide metabolism
4667 U 60S ribosomal protein L11 P62913 21/20 5.9 2 Binds to 5S ribosomal RNA
4678 U S-phase kinase-associated protein 1 (SKP1)a P63208 20/19 4.6 2 Ubl conjugation pathway
The function and/or biological process were obtained from the UniProt database [19].
Spot, spot number; FC, fold change; U, unique; MW, molecular weight (kDa); pI exp, isoelectric point as determined from the two-dimensional gel experiments;
Pep, number of unique peptides. aProteins used for RT-qPCR validation. The number after the protein name indicates the additional spot in which the protein
was found.
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(AR), estrogen receptor alpha (ERa) and estrogen recep-
tor beta (ERb), were quantified by RT-qPCR (Figure
3C). RT-qPCR analyses revealed that the overexpression
of 17b-HSD1 in MCF7 cells induces an increase in the
mRNA expression of 17b-HSD5, STS, 17b-HSD12 and
ERb by 20, 33, 73 and 120%, respectively, while inhibit-
ing AR expression by 64%. The highest mRNA-level
modulation was observed with ERa, which exhibited a
significant increase of 171%. The increase in 17b-HSD7
was small, whereas no modulation was observed with
17b-HSD2 and aromatase expression (Figure 3C and
3D). These results show that the expression of 17b-
HSD1 can influence that of other genes implicated in
estradiol metabolism and action, especially the estrogen
receptors (ER), and further confirm the enzyme role in
producing active estrogen and inactivation of DHT [11].
Correlation between 17b-HSD1 and nm23-H1 expression
Since our proteomic and RT-qPCR data showed that
17b-HSD1 overexpression increases the metastasis inhi-
bition factor nm23-H1 mRNA and protein levels, we
were interested to know if 17b-HSD1 knockdown
would decrease nm23-H1 expression. T47D cells were
chosen for this investigation because the cell line
expresses a high level of endogenous 17b-HSD1
[11,15,22]. Cells were transfected with 17b-HSD1-speci-
fic siRNA and with scramble siRNA (control siRNA)
and total RNA was extracted 48 hours after transfec-
tion. The 17b-HSD1 and nm23-H1 mRNAs were quan-
tified by RT-qPCR. The efficacy of 17b-HSD1
knockdown by its specific siRNA was demonstrated
since 92% inhibition of 17b-HSD1 mRNA was observed
(Figure 3E). Nm23-H1 mRNA levels were compared in
control-siRNA- and 17b-HSD1-siRNA-transfected T47D
cells. A decrease of 31% of nm23-H1 mRNA expression
was observed after 17b-HSD1 gene knockdown (Figure
3F). These results, combined with proteomic and RT-
qPCR analyses of MCF7 and MCF7-17bHSD1, indicate
a positive correlation between 17b-HSD1 and nm23-H1
expression.
Regulation of cell migration by 17b-HSD1
To investigate if 17b-HSD1 could have any implication
in cancer metastasis, we evaluated the effect of its
expression on MCF7 cell migration by means of a
wound-healing assay. The migrations of WT MCF7 and
MCF7-17bHSD1 cells were first compared. We found
that cell migration was higher in MCF7-17bHSD1 stably
overexpressing 17b-HSD1 than in WT MCF7 cells,
showing that MCF7-17bHSD1 cells have more ability to
invade a scratch than WT MCF7 cells (Figure 4A and
4B). The effect of 17b-HSD1 knockdown on cell migra-
tion was then tested in MCF7-17bHSD1 cells trans-
fected with 17b-HSD1-specific siRNAs or control
siRNA. Semiquantitative RT-PCR analysis showed a 98%
decrease of 17b-HSD1 mRNA after transfection of
MCF7-17bHSD1 cells with specific siRNAs as compared
to the control cells (Figure 4C). Importantly, the knock-
down of 17b-HSD1 in MCF7-17bHSD1 cells was asso-
ciated with a decreased cell migration (by 16.1%, P <
0.05) compared to cells transfected with control siRNA
(Figure 4D and 4E). Taken together, these results show
that 17b-HSD1 expression is positively correlated with
MCF7 cell migration.
























































Figure 2 Functions and cellular locations of the differentially expressed proteins between wild type MCF7 cells and MCF7 cells stably
transfected with 17b-HSD1 (MCF7-17bHSD1). The Uniprot database [19] was used to generate the cellular location and the molecular
function and/or biological process of each of the 59 nonredundant (distinct) proteins identified by mass spectrometry analysis as differentially
regulated. Of the 59 distinct proteins, the percentages of proteins involved in each molecular function and found in each cellular location are
indicated in brackets.
Aka et al. Breast Cancer Research 2012, 14:R92
http://breast-cancer-research.com/content/14/3/R92
Page 8 of 14
A      C 
B      D
 














































































































































Figure 3 mRNA and protein level modulation by 17beta-hydroxysteroid dehydrogenase type 1 (17b-HSD1). (A) Expression of 17b-HSD1,
proliferating cell nuclear antigen (PCNA), nm23-H1, and BRCA2 and CDKN1A interacting protein (BCCIP) in wild type (WT) MCF7 cells and MCF7
cells stably transfected with 17b-HSD1 (MCF7-17bHSD1) revealed by western blots. b-actin protein amount was used as internal control. The
arrows show the positions of the protein bands. (B) The western blot bands in (A) were quantified, and the ratio between the protein signals of
interest and the b-actin signal was calculated to determine the relative protein expression values for WT MCF7 and MCF7-17bHSD1. (C) Reverse
transcription quantitative real-time polymerase chain reaction (RT-qPCR) values (mRNA copies/µg total RNA) of mRNAs encoding proteins
involved in estradiol production and/or action in WT MCF7 and MCF7-17bHSD1. N, negligible (RT-qPCR values < 1,000); 0, mRNA not detected
after many rounds of amplification. (D) Relative mRNA expression values of enzymes involved in estradiol production in MCF7-17bHSD1 as
compared to WT MCF7. The mRNA levels in WT MCF7 cells were fixed at 100. (E) and (F) Relative 17b-HSD1 (E) and nm23-H1 (F) mRNA
expression in siRNA-transfected T47D cells. T47D cells were transfected with 17b-HSD1 siRNA or control siRNA and 17b-HSD1 mRNA was
quantified by RT-qPCR. mRNA quantity in control-siRNA transfected cells was fixed at 100. Error bars represent standard deviation. *P <0.05
analyzed by Student’s t-test.
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Discussion
Proteomic modifications of MCF7 cells in response to
17b-HSD1 overexpression
In a previous study, we showed that modulating the
expression of the steroid-converting enzyme 17b-HSD1 in
MCF7 and T47D cells led to a differential cell growth com-
pared to the parent cells, cultured in medium containing
E2 [11]. The present study compared the proteomes of the
stably transfected MCF7-17bHSD1 and WT MCF7 cells
and established the first differential profile of a cell line
overexpressing the enzyme and its parent cell. Our proteo-
mics data revealed that increasing 17b-HSD1 expression
significantly modulates the expression of proteins involved
in various functional activities such as cell cycle, cell
growth, apoptosis and carcinogenesis. Examples include
PCNA, BCCIP and peroxiredoxin-2. Considering the func-
tions of these enzymes in breast cancer, the directions in
which their expression is regulated by 17b-HSD1 agree
with its role in increasing breast cancer cell growth. This
can reveal the factors that make 17b-HSD1 stably-trans-
fected MCF7 cells grow faster than the WT MCF7 cells
when cultured in medium containing E2 [11]. The four
most represented functional activities for the modulated
proteins are metabolism (examples include alpha-N-acetyl-
galactosaminidase and mitochondrial enoyl-CoA hydra-
tase), mRNA processing (eukaryotic initiation factor 4A-III
and arginine/serine-rich splicing factor 2), protein bio-
synthesis (elongation factor 1-gamma) and transport
(endoplasmic reticulum resident protein ERp29 and
RAB11B protein) (Figure 2, Table 1 and Additional file 2).
The predominant locations of differentially expressed pro-
teins in the nucleus and cytoplasm might reflect their func-
tions in mRNA processing and protein biosynthesis. These
four functions are known to be essential in steroid signal-
ling which involves fast nongenomic activities (including
the transport and metabolism of signalling molecules) and
genomic mechanisms mediated by their specific receptors;
these later mechanisms comprise gene transcription (RNA
formation and mRNA processing) and protein biosynthesis
[14] related to cell growth and regulation. The presence of
E2 in MCF7 and MCF7-17bHSD cell culture medium and
the change in expression of a large number of proteins
involved in these four functions following 17b-HSD1 over-
expression suggest a modulation of E2 effects by 17b-
HSD1. In fact, 17b-HSD enzymes fit well into the concept
of pre-receptor regulation of steroid action as they effi-
ciently alter the binding of steroids to their genomic and
nongenomic receptors and effectors, acting as a metabolic
switch prior to the function of these receptors [14]. The
concept of pre-receptor regulation of E2 action by 17b-
HSD1 corroborates with its effect on the modulation of E2
responsiveness of pS2 genes in T47D cells [11], since E2
exerts its biological effect on breast cancer predominantly
via the mediation of ERa and ERb [23,24]. The strong sti-
mulation of ERa (171% increase) and ERb (120% increase)
gene expression and the protein regulation of a large num-
ber of non-estrogen-responsive genes caused by 17b-HSD1
overexpression further suggest that the ligand-independent
transcriptions of ER target genes are also modulated by the
enzyme. Indeed, this stimulation can influence the regula-
tion of gene transcription by ER.
A recent study showed a high level of 17b-HSD2 in
the WT MCF7 cell line [25]. Our data, on the contrary,
showed negligible expression of 17b-HSD2 in this cell
line, in conformity with other studies [15,26]. While
17b-HSD1 has no effect on the expression of the E2-
inactivating enzyme 17b-HSD2, it increases the mRNA
levels of the E2-producing enzymes 17b-HSDs type 5,
7 and 12, with type 12 having a significant, and the
highest increase. This suggests a concerted action of
reductive 17b-HSDs to accelerate the cellular E2
biosynthesis.
Table 2 mRNA quantification by RT-qPCR of genes involved in breast cancer cell proliferation within wild type MCF7
and MCF7 cells stably transfected with 17b-HSD1 (MCF7-17bHSD1) and comparison with two-dimensional gel data.





RT-qPCR value (mRNA copies/µg total RNA)
Proliferating cell nuclear antigen (PCNA) 1,599,813 4,483,982 + 2.8 Yesc
Peroxiredoxin 2 4,078,760 8,585,424 + 2.1 Noc
Metastasis inhibition factor nm23 (nm23-H1) 5,366,763 19,356,416 + 3.6 Yesc
S-phase kinase-associated protein 1 (SKP1) 3,810,452 5,714,509 + 1.5 Yes
BRCA2 and CDKN1A interacting protein (BCCIP) 345,839 1,074,647 + 3.1 Noc
Ribonuclease/angiogenin inhibitor 1 (RNH1) 1,015,193 727,425 - 1.4 Yesc
Standard deviations were < 10% of duplicates.
aProteins were selected for reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) after their identification by mass spectrometry
analysis of two-dimensional (2-D) gel protein spots.
bFold regulation of mRNA levels in MCF7 cells stably transfected with 17b-HSD1 (MCF7-17bHSD1) compared to wild type MCF7 cells; +, fold increase; -, fold
decrease).
cMass spectrometry analysis showed that the two-dimensional spot contained several proteins including the indicated protein.
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Breast cancer cell migration is increased by 17b-HSD1
despite a positive correlation with the metastasis
suppressor gene nm23-H1
Two estrogen-responsive genes involved in metastasis
regulation, cathepsin D (Table 1) [27] and nm23-H1
[28-30], were found to be differentially expressed at the
protein levels following 17b-HSD1 overexpression.
Cathepsin D, an independent marker of poor prognosis
in breast cancer that correlates with the incidence of
clinical metastasis [31], was downregulated. Nm23-H1
was upregulated at the protein level, its mRNA
increased 3.6-fold with 17b-HSD1 overexpression (in
MCF7-17bHSD1), and its gene expression decreased by
31% following 17b-HSD1 knockdown in T47D. These
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Figure 4 17beta-hydroxysteroid dehydrogenase type 1 (17b-HSD1) is a positive regulator of MCF7 cell migration. (A) and (B)
Comparison of cell migration between wild type (WT) MCF7 and MCF7 cells stably transfected with 17b-HSD1 (MCF7-17bHSD1). A scratch was
applied to WT MCF7 and MCF7-17bHSD1 cells confluent in dishes (3.5 cm diameter) and the ability to invade the scratch was measured. (A) The
relative migration of WT MCF7 and MCF7-17bHSD1 cells at 24 and 36 hours post-scratch was quantified. The scratch widths, two near the
border and three in the middle of the scratch (as shown in B) were measured at the indicated time points using the NIH ImageJ software and
data were used to calculate the percentage of migration. (B) Results showed that WT MCF7 cells have less ability to invade the scratch than the
MCF7-17bHSD1 cells. Lines represent measurements made to assess modifications in scratch widths. (C) 17b-HSD1 knockdown by siRNA in
MCF7-17bHSD1 cells. Semiquantitative reverse transcription polymerase chain reaction (RT-PCR) was performed using 17b-HSD1 and b-actin
primers and total RNA extracted from MCF7-17bHSD1 cells transfected with 17b-HSD1-specific siRNAs or control siRNA. (D) and (E) Effect of 17b-
HSD1 knockdown on MCF7-17bHSD1 cell migration. MCF7-17bHSD1 cells were transfected with 17b-HSD1-specific siRNAs or control siRNA for
48 hours before creating a wound by scraping the cell monolayer. Cells transfected with 17b-HSD1 siRNA have less ability to invade the scratch
than cells transfected with control siRNA. All experiments were done in quadruplicate, and representative images of cell progression in the
scratch are shown. Error bars represent standard deviation. *P <0.05 analyzed by Student’s t-test.
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results demonstrate that 17b-HSD1 expression is posi-
tively and closely correlated to nm23-H1 expression.
The downregulation of cathepsin D can be related to
the increase of nm23-H1 as their negative correlation
has already been demonstrated [27]. Patients with malig-
nant melanoma who develop metastases during the first
two years after diagnosis have significantly lower levels
of tumor nm23-H1 expression (56% of the mean value)
compared to patients with less aggressive disease (164%)
[32]. The nm23-H1 gene, NM23, is known to function
as a tumor metastasis suppressor gene and its transcript
level is reduced in highly metastatic cells [32,33]. It has
been reported that nm23-H1 inhibits cell migration and
cancer metastasis by modulating the activity of Rho-
family small GTPase enzymes, which are known to play
a key role in the actin cytoskeleton dynamics required
for cancer cell migration and invasion [34]. In agree-
ment with the strong enhancement of nm23-H1 mRNA
level by 17b-HSD1, we hypothesized the implication of
17b-HSD1 in tumor metastasis. Until now, quantitative
analyses of the transcripts of estrogen-producing
enzymes in breast cancer metastases have not demon-
strated any significant association between 17b-HSD1
mRNA level and metastases, although the sulfatase and
aromatase mRNA levels were significantly associated
with the presence of metastases in some studies [35-37].
Using the wound-healing assay, we demonstrated for the
first time that increasing 17b-HSD1 expression led to
the increase of MCF7 cell migration while 17b-HSD1
knockdown decreased MCF7 cell migration. Our study
thus shows for the first time that 17b-HSD1 expression
is positively correlated with the migration of the breast
cancer cell line MCF7, revealing its role as a positive
regulator of cell migration, contrary to nm23-H1.
E2-induced time-dependent increases in the abundance
of nm23-H1 mRNA and protein are coincident with the
expression level of its receptor ERa [29], which has been
shown to interact with the non-metastasis gene nm23-H1
[27,29]. Since our cell models were cultivated in the pre-
sence of E2 and our data showed that 17b-HSD1 positively
regulates ERa mRNA level, one could postulate that the
positive correlation between nm23-H1 and 17b-HSD1
expression is coincident with the activation of nm23-H1
expression by ERa and E2, which are increased with 17b-
HSD1 expression. Thus, 17b-HSD1 may indirectly affect
nm23-H1 expression via ERa action. On the other hand,
the increase of MCF7 cell migration by 17b-HSD1,
demonstrated in the present study, corroborates with its
role in stimulating breast cancer cell growth [11] and the
poor prognosis for patients in whom 17b-HSD1 is highly
expressed in the breast [13]. This may open a new study
on the role of this multifunctional steroid enzyme, that
appeared early in evolution [38,39], revealing a complex
mechanism in breast cancer with its expression. The latter
may involve protein-protein and protein-DNA interactions
among ERa, NM23, 17b-HSD1, AR, cathepsin D and
other genes and proteins. The role of 17b-HSD1 is in
keeping with evidence from recent studies [22,40].
Conclusions
Our study demonstrates that 17b-HSD1 affects breast
cancer cell proteome and modulates expression of sev-
eral genes at both mRNA and protein levels. Among the
individual mRNA and proteins for which the regulation
was investigated, the most strongly modulated by 17b-
HSD1 are ERa and nm23-H1. Intriguing observations
are that although 17b-HSD1 strongly stimulates nm23-
H1 expression, it is associated with an increased MCF7
cell migration. Here, we report the general study of pro-
teomics with 17b-HSD1 expression modification, while
the mechanism on cell migration modification opens a
new study of interest for additional roles of the well-
known steroid-converting enzyme. It can be of great
interest to investigate 17b-HSD1 role in cancer metasta-
sis formation.
Additional material
Additional file 1: Table showing the primers used for reverse
transcription quantitative real-time polymerase chain reaction.
Additional file 2: Table of additional data for mass spectrometry
identification of proteins differentially expressed between wild type
MCF7 and MCF7 stably transfected with 17b-HSD1 (MCF7-
17bHSD1).
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